Opinion on Pharmaceutical Manufacturers in Europe

Published within

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

UK cardiovascular disease: statins for all?

Researchers have suggested that in order to tackle heart disease in the country, nearly all middle-aged UK men should receive statins as preventative medicine. This claim points to the great need for new guidelines concerning statin use. However, new guidelines alone might not be enough to combat the prevalence and high cost of cardiovascular disease as more effective measures are required.

Published By Datamonitor
26 May 2006
CommentWire
CommentWire

Novartis: building its antiviral arsenal

Novartis has announced a $507 million licensing deal with Human Genome Sciences for Albuferon, giving Novartis rights to co-promote the hepatitis C drug candidate in the US, with exclusive marketing and promotion rights outside the US. This is the Swiss firm's latest step in its strategy to build a versatile hepatitis C portfolio and become a leading player in this high-growth market.

Published By Datamonitor
06 Jun 2006
CommentWire
CommentWire

Novartis: continuing its infectious diseases drive

Novartis has bolstered its infectious disease pipeline with two acquisitions in as many days. The Swiss firm has signed a global agreement with US-based Human Genome Sciences for hepatitis C drug candidate Albuferon and made an offer for UK-based anti-infectives developer NeuTec Pharma.

Published By Datamonitor
07 Jun 2006
Expert View
Expert View

Depression sufferers still reluctant to see physician

While the number of individuals with major depressive disorder (MDD) is set to grow only minimally in next two decades, the condition still represents a key health risk, for both society and the individual. For example, MDD is a leading cause of disability and under-diagnosis remains a problem. Furthermore, the leading classes of MDD drugs have been linked to increased suicidality.

Published By Datamonitor
07 Jun 2006
ResearchWire
ResearchWire

Influenza vaccines: pandemic threat to fuel market growth

Published By Datamonitor
08 Jun 2006
ResearchWire
ResearchWire

OTC healthcare: Turkey gobbles up medicated skincare

Published By Datamonitor
16 Jun 2006
ResearchWire
ResearchWire

Endo: no pain, all gain for Lidoderm

Published By Datamonitor
16 Jun 2006
CommentWire
CommentWire

EULAR: Roche and BMS target RA market

By presenting new data at the rheumatology conference currently being held in Amsterdam, Roche and Bristol-Myers Squibb are hoping to encourage uptake of their recently approved rheumatoid arthritis drugs. Although the data illustrates the addition of valuable new treatment options, an increasingly competitive market is set to limit the impact of Rituxan and Orencia in this indication.

Published By Datamonitor
23 Jun 2006
CommentWire
CommentWire

Bayer/Schering: done deal leaves Merck KGaA standing

Despite the looming deadline for acceptance and significant stumbling block posed by Merck KGaA, Bayer Group has successfully completed its $21 billion takeover of Berlin-based Schering AG. The deal creates Germany's leading healthcare company, and also provides Merck with an instant capital injection. However, Merck will itself need to look to acquisitions if it is to secure long-term growth.

Published By Datamonitor
23 Jun 2006
ResearchWire
ResearchWire

mAbs: new asthma therapies to drive the market

Published By Datamonitor
23 Jun 2006

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

No help is available.